This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bimatoprost Versus Travoprost at Cairo University

This study has been completed.
Information provided by:
Cairo University Identifier:
First received: March 23, 2010
Last updated: NA
Last verified: January 2008
History: No changes posted

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Glaucoma Ocular Hypertension

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.

Resource links provided by NLM:

Further study details as provided by Cairo University:

Primary Outcome Measures:
  • Percentage of intraocular pressure lowering of bimatoprost versus travoprost.

Secondary Outcome Measures:
  • Rate of development of complications.

Bimatoprost versus Travoprost


Ages Eligible for Study:   20 Years to 72 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Hospital Based Study at Cairo University and Al Nour Eye Hospital

Inclusion Criteria:

  • Glaucoma and Ocular Hypertension

Exclusion Criteria:

  • Any ocular disease or medication that may raise the intraocular pressure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01092273

Cairo University
Cairo, Egypt, 11431
Sponsors and Collaborators
Cairo University
  More Information

Additional Information: Identifier: NCT01092273     History of Changes
Other Study ID Numbers: Prostaglandins-Cairo-1A
Study First Received: March 23, 2010
Last Updated: March 23, 2010

Keywords provided by Cairo University:
Glaucoma and Ocular Hypertension

Additional relevant MeSH terms:
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Antihypertensive Agents processed this record on June 26, 2017